Please use this identifier to cite or link to this item:
Title: Performance of the Xpert MTB/RIF Ultra assay for determining cause of death by tuberculosis in tissue samples obtained by minimally invasive autopsies
Author: García Basteiro, Alberto L.
Hurtado, Juan Carlos
Castillo, Paola
Fernandes, Fabiola
Navarro, Mireia
Lovane, Lucilia
Casas, Isaac
Quintó, Llorenç
Jordao, Dercio
Smail, Mamudo Rafik
Lorenzoni, Cesaltina
Carrilho, Carla
Sanz, Ariadna
Rakislova, Natalia
Mira, Aurea
Álvarez Martínez, Míriam
Cossa, Anelsio
Cobelens, Frank
Mandomando, Inácio
Vila Estapé, Jordi
Bassat Orellana, Quique
Menéndez, Clara
Ordi i Majà, Jaume
Martínez Yoldi, Miguel Julián
Keywords: Tuberculosi
Reacció en cadena de la polimerasa
Polymerase chain reaction
Issue Date: 11-Jul-2021
Publisher: American College of Chest Physicians
Abstract: An estimated 1.5 million deaths were attributable to TB in 2018.1 However, some uncertainty exists as to the exact global figures, given that approximately 30% of incident cases are not diagnosed, and because of the difficulties of ascertaining TB as cause of death (CoD).2 Undoubtedly, complete diagnostic autopsies (CDAs) constitute the gold standard for establishing a diagnosis of TB at death. However, CDAs are seldom performed in high-TB-burden countries because of the scarcity of trained pathologists, the time-consuming nature of the procedure, and the meager acceptability of the practice by relatives.3 In recent years, an alternative minimally invasive autopsy (MIA), a procedure well accepted by the next of kin, has been developed.4 ,5 MIA can be conducted relatively rapidly with the use of biopsy needles for sampling key organs, which leave barely visible marks, which is thus more acceptable to relatives. This method has shown good sensitivity for diagnosing TB as CoD.6 Nonetheless, MIA has thus far used standard histological and microbiological approaches for TB diagnosis (identification of granulomatous lesions, acid-fast bacilli smears, in-house polymerase chain reaction methods),7 which remain time consuming, require specific expertise, and have limited sensitivity. Thus, we evaluated the diagnostic accuracy of the molecular Xpert MTB/RIF Ultra (hereafter referred to as Xpert Ultra) assay in samples obtained by MIA to detect CoD by TB.
Note: Reproducció del document publicat a:
It is part of: Chest, 2021, vol. 159, num. 1, p. 103-107
Related resource:
ISSN: 0012-3692
Appears in Collections:Articles publicats en revistes (ISGlobal)
Articles publicats en revistes (Fonaments Clínics)

Files in This Item:
File Description SizeFormat 
706093.pdf189.71 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons